The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a
Move For Migraine Migraine remains an overlooked and misunderstood condition in many parts of Europe, including Belgium. The disease suffers from a lack of recognition and understanding, even from the first concerned parties (patients, caregivers, employers, etc.). This comes at a significant burden for the patients and at a high cost for society (1,650,000 working
For Industry. Cooperating in finding solutions for patients. WHAT CAN EMHA DO FOR THE INDUSTRY. Cooperating in finding solutions for patients. Working together is the only way to find effective and lasting solutions for migraine sufferers. By encouraging research, supporting projects and working to distribute reliable information, we can achieve a better quality of life
INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least
First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity
The impact of headache in Europe THE IMPACT OF HEADACHE IN EUROPE — EVIDENCE FROM THE EUROLIGHT STUDYEurolight was a cross-sectional questionnaire-based survey in 10 European countries. Sampling was population-based in six (Germany, Italy, Lithuania, Luxembourg, Netherlands, Spain) and from consecutive patients attending general practitioners (GPs) for any reason in three (Austria, France, UK). Additional
Poor medical care for people with migraine in Europe. EUROLIGHT STUDY—Migraine in Europe.Migraine is prevalent everywhere, and disabling. It is also neglected: consequently, it is underdiagnosed and undertreated. We analysed data from the Eurolight study on consultations and utilization of migraine-specific medications as indicators of adequacy of medical care in Europe. The study Migraine is
We are an alliance The European Migraine and Headache Alliance is a non-profit patient association, which functions as an umbrella organisation for different patient groups across Europe. The Alliance was establi- shed in 2006 and since then we represent more than 30 patient groups across the continent. Also, we work closely with International Associates in Canada, US, Turkey, Argentina,
Migraine in the EU: EMHA’s ‘Access to Care’ survey reveals shocking hurdles for patients to overcome and disparities in the EU. Presented at the Migraine in the EU: Lifting the barriers to treatment webinar. 29 September 2021, Brussels, Belgium. The European Migraine & Headache Alliance (EMHA) organised a webinar “Migraine in the EU: Lifting the
Laboratory-made antibody Erenumab blocks neural brain pathway and is first new treatment for attacks approved in 20 years A new migraine drug that can halve the length of time sufferers are laid low by the debilitating condition has been hailed as an “incredibly important” advance. Erenumab, a laboratory-made antibody that blocks a neural brain pathway
